Literature DB >> 30171028

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

Marie Luise Hütter-Krönke1, Walter Fiedler2, Andrea Kündgen3, Jürgen Krauter4,5, Marie von Lilienfeld-Toal6, Hartmut Döhner7, Richard F Schlenk7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30171028      PMCID： PMC6355481          DOI： 10.3324/haematol.2018.199794

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

Authors:  R A Mesa; A Tefferi; C-Yang Li; D P Steensma
Journal:  Leukemia       Date:  2006-09-21       Impact factor: 11.528

2.  A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Authors:  Todd A Fehniger; Geoffrey L Uy; Kathryn Trinkaus; Alissa D Nelson; Jeffery Demland; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Ravi Vij
Journal:  Blood       Date:  2010-11-04       Impact factor: 22.113

3.  A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.

Authors:  Amer M Zeidan; B Douglas Smith; Hetty E Carraway; Ivana Gojo; Amy DeZern; Steven D Gore
Journal:  Br J Haematol       Date:  2016-10-28       Impact factor: 6.998

4.  Dose escalation of lenalidomide in relapsed or refractory acute leukemias.

Authors:  William Blum; Rebecca B Klisovic; Heiko Becker; Xiaoxia Yang; Darlene M Rozewski; Mitch A Phelps; Ramiro Garzon; Alison Walker; Jason C Chandler; Susan P Whitman; John Curfman; Shujun Liu; Larry Schaaf; Jon Mickle; Cheryl Kefauver; Steven M Devine; Michael R Grever; Guido Marcucci; John C Byrd
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

5.  Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

Authors:  Todd A Fehniger; John C Byrd; Guido Marcucci; Camille N Abboud; Cheryl Kefauver; Jacqueline E Payton; Ravi Vij; William Blum
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

6.  A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.

Authors:  Elizabeth A Griffiths; William E Brady; Wei Tan; Carlos E Vigil; James E Thompson; Laurie A Ford; Noelle M Dickey; Heather L Bashaw; Jill Sperrazza; Meir Wetzler; Eunice S Wang
Journal:  Leuk Res       Date:  2016-02-16       Impact factor: 3.156

7.  Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

Authors:  Giuseppe Visani; Felicetto Ferrara; Francesco Di Raimondo; Federica Loscocco; Fabio Fuligni; Stefania Paolini; Valentina Zammit; Eleonora Spina; Marco Rocchi; Axel Visani; Pier Paolo Piccaluga; Alessandro Isidori
Journal:  Leuk Res       Date:  2017-09-25       Impact factor: 3.156

8.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

9.  Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.

Authors:  Bruno C Medeiros; Kelly McCaul; Suman Kambhampati; Daniel A Pollyea; Rajat Kumar; Lewis R Silverman; Andrea Kew; Lalit Saini; C L Beach; Ravi Vij; Xiwei Wang; Jim Zhong; Robert Peter Gale
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941
  9 in total
  3 in total

Review 1.  Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look.

Authors:  Lena Behrmann; Jasmin Wellbrock; Walter Fiedler
Journal:  Front Oncol       Date:  2018-10-12       Impact factor: 6.244

Review 2.  Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.

Authors:  Yiyi Yao; Fenglin Li; Jiansong Huang; Jie Jin; Huafeng Wang
Journal:  Exp Hematol Oncol       Date:  2021-07-10

3.  Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.

Authors:  Peng Zhao; Ming Ni; Dan Ma; Qin Fang; Yan Zhang; Yanju Li; Yi Huang; Ying Chen; Xiao Chai; Yun Zhan; Yan Li; Qian Kang; Mei Zhao; Min Liu; Fengqi Zhang; Shisi Huang; Shuangshuang Wen; Bo Deng; Jishi Wang
Journal:  Ann Hematol       Date:  2021-09-27       Impact factor: 3.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.